Lamellar Ichthyosis Market is segmented By Treatment Type (Topical Treatments (Emollients, Keratolytics), Systemic Treatments (Retinoids, Other oral m....
Market Size in USD
CAGR4.46%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 4.46% |
Market Concentration | High |
Major Players | Amgen Inc., Eli Lilly and Company, Pfizer Inc., Novartis AG, AbbVie Inc. |
The Global Lamellar Ichthyosis Market is estimated to be valued at USD 5.30 Billion in 2024 and is expected to reach USD 7.21 Billion by 2031, growing at a compound annual growth rate (CAGR) of 4.46% from 2024 to 2031. The increasing prevalence of rare genetic skin disorders and various treatment options driving the market growth. Various government initiatives to increase awareness regarding rare skin diseases and improving access to diagnosis and treatment across the globe is contributing to the market expansion.
The Global Lamellar Ichthyosis Market is expected to witness steady growth over the forecast period. The development of new combination therapies with improved efficacy and reduced side-effects is creating new opportunities in the market. Moreover, the increasing focus of major pharmaceutical players on rare disease portfolio through mergers, acquisitions and licensing deals will further support market growth in coming years. However, lack of approved treatment options for lamellar ichthyosis and high treatment cost pose challenges to market growth.